Sanofi Highlights MS Asset After Solid Q4

BTK Inhibitor Entering Phase III Soon

06 Feb 2020

• By Sten Stovall

The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.

Sanofi_Berlin — Sanofi is refocusing its business model and narrowing therapeutic priorities • Source: Shutterstock

Sanofi Highlights MS Asset After Solid Q4

BTK Inhibitor Entering Phase III Soon

More from Earnings

More from Business